No photo of Sunandana Chandra

View Scopus Profile

Sunandana Chandra

  • 747 Citations
20122023

Research output per year

If you made any changes in Pure these will be visible here soon.

Personal profile

Research Interests

I have an interest in the development of clinical trials, as well as studying novel biomarkers that may be used as prognostic and predictive tools in the management of melanoma and other advanced skin cancers, as well as cancer of unknown primary.

Training Experience

2011Residency, Case Western Reserve University Hospital
2014Fellowship, New York University Medical Center

Education/Academic qualification

MD, Michigan State University

… → 2008

MS, Michigan State University

… → 2003

Research interests

  • Cancer of Unknown Primary
  • Clinical Research
  • Drug Discovery
  • Melanoma
  • Skin Cancer

Fingerprint Dive into the research topics where Sunandana Chandra is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 4 Similar Profiles

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Grants

Prot #R2810-ONC-1788: A Randomized, Placebo-Controlled, Double-Blind Study of Adjuvant Cemiplimab Versus Placebo after Surgery and Radiation Therapy in Patients with High Risk Cutaneous Squamous Cell Carcinoma (CSCC)

Chandra, S.

ICON Clinical Research Limited, Regeneron Pharmaceuticals, Inc.

2/25/20 → 2/25/23

Project: Research project

Prot #R2810-ONC-1806: Cemiplimab Survivorship Epidemiology (CASE) Study

Chandra, S.

inVentiv Health Clinical, Regeneron Pharmaceuticals, Inc.

12/5/19 → 12/5/22

Project: Research project

Prot #HCRN MEL17-309/NU G18M02: Phase II Single-Arm Multi-Center Study of Adjuvant Ipilimumab in Combination with Nivolumab in Subjects with High-Risk Ocular Melanoma

Chandra, S.

Hoosier Cancer Research Network, Inc., Bristol-Myers Squibb Company

10/22/19 → 10/22/22

Project: Research project

Prot #CA224083: A Phase 1/2a Study to Evaluate the Safety, Tolerability, and Efficacy of Relatlimab Administered in Combination with Ipilimumab or Ipilimumab Alone in Participants with Unresectable or Metastatic Melanoma Who Have Progressed on Anti-PD-1 T

Chandra, S.

Bristol-Myers Squibb Company

9/25/19 → 9/25/22

Project: Research project

Prot #GO40558: A Phase II, Open-Label, Multicenter, Randomized Study Of The Efficacy And Safety Of RO7198457 In Combination With Pembrolizumab Versus Pembrolizumab In Patients With Previously Untreated Advanced Melanoma

Chandra, S.

Covance Inc., Genentech, Inc.

9/11/19 → 9/11/22

Project: Research project

Research Output

CASE (CemiplimAb-rwlc Survivorship and Epidemiology) study in advanced cutaneous squamous cell carcinoma

Migden, M. R., Chandra, S., Rabinowits, G., Chen, C. I., Desai, J., Seluzhytsky, A., Sasane, M., Campanelli, B., Chen, Z., Freeman, M. L., Ibrahim, S. F., Khushalani, N. I., Andria, M. & Ruiz, E., Jan 1 2020, In : Future Oncology. 16, 4, p. 11-19 9 p.

Research output: Contribution to journal › Article

Open Access

    • Sebaceous carcinoma: controversies and their evidence for clinical practice

    Kibbi, N., Worley, B., Owen, J. L., Kelm, R. C., Bichakjian, C. K., Chandra, S., Demirci, H., Kim, J. Y. S., Nehal, K. S., Thomas, J. R., Samuelson, E. P. & Alam, M., Jan 1 2020, In : Archives of Dermatological Research. 312, 1, p. 25-31 7 p.

    Research output: Contribution to journal › Review article

    • A case report of clonal EBV-like memory CD4+ T cell activation in fatal checkpoint inhibitor-induced encephalitis

    Johnson, D. B., McDonnell, W. J., Gonzalez-Ericsson, P. I., Al-Rohil, R. N., Mobley, B. C., Salem, J. E., Wang, D. Y., Sanchez, V., Wang, Y., Chastain, C. A., Barker, K., Liang, Y., Warren, S., Beechem, J. M., Menzies, A. M., Tio, M., Long, G. V., Cohen, J. V., Guidon, A. C., O’Hare, M. & 13 others, Chandra, S., Chowdhary, A., Lebrun-Vignes, B., Goldinger, S. M., Rushing, E. J., Buchbinder, E. I., Mallal, S. A., Shi, C., Xu, Y., Moslehi, J. J., Sanders, M. E., Sosman, J. A. & Balko, J. M., Aug 1 2019, In : Nature Medicine. 25, 8, p. 1243-1250 8 p.

    Research output: Contribution to journal › Letter

    • 4 Scopus citations

    Adverse Events Associated with Immune Checkpoint Inhibitors - Reply

    Johnson, D. B., Chandra, S. & Sosman, J. A., Mar 26 2019, In : JAMA - Journal of the American Medical Association. 321, 12, p. 1219-1220 2 p.

    Research output: Contribution to journal › Letter

    Clinical characterization of colitis arising from anti-PD-1 based therapy

    Wang, D. Y., Mooradian, M. J., Kim, D. W., Shah, N. J., Fenton, S. E., Conry, R. M., Mehta, R., Silk, A. W., Zhou, A., Compton, M. L., Al-Rohil, R. N., Lee, S., Voorhees, A. L., Ha, L., McKee, S., Norrell, J. T., Mehnert, J., Puzanov, I., Sosman, J. A., Chandra, S. & 5 others, Gibney, G. T., Rapisuwon, S., Eroglu, Z., Sullivan, R. & Johnson, D. B., Jan 2 2019, In : OncoImmunology. 8, 1, e1524695.

    Research output: Contribution to journal › Article

    • 3 Scopus citations